PT-141, known generically as bremelanotide and commercially as Vyleesi, is a cyclic heptapeptide melanocortin receptor agonist that the FDA approved in June 2019 for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. It holds a unique position in pharmacology as the first and only FDA-approved treatment for female sexual dysfunction that works through a central nervous system mechanism rather than a hormonal or vascular pathway. Derived from research on Melanotan II, PT-141 represents the successful clinical translation of melanocortin science into an approved therapeutic, targeting sexual desire at its neurological origin in the hypothalamus.
Primary reported benefits include:
- FDA-approved treatment for hypoactive sexual desire disorder in premenopausal women
- Acts centrally through melanocortin receptors to enhance sexual desire and arousal
- Works through a mechanism distinct from PDE5 inhibitors (Viagra, Cialis)
- On-demand dosing with no daily pill required
- Investigated for male sexual dysfunction including erectile dysfunction and low libido
What Is PT-141 (Bremelanotide)?
PT-141 (bremelanotide) is a synthetic cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone (alpha-MSH) with the amino acid sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, a molecular formula of C50H68N14O10, and a molecular weight of 1025.16 g/mol. It is cyclized via a lactam bridge between the Asp and Lys residues, giving it a constrained three-dimensional structure that provides both high receptor affinity and resistance to enzymatic degradation.
History and Development
The origins of PT-141 trace directly to the Melanotan II research program at the University of Arizona in the 1980s, where scientists were developing alpha-MSH analogs as potential sunless tanning agents. During an early self-experiment, researcher Dr. Mac Hadley accidentally injected double the intended dose of Melanotan II and experienced a prolonged erection lasting eight hours, along with severe nausea. This unexpected finding redirected research toward sexual dysfunction applications.
Palatin Technologies acquired the rights to develop the sexual function applications of Melanotan II. By 2000, Palatin had ceased development of Melanotan II itself and synthesized bremelanotide, an active metabolite of Melanotan II that differs structurally by having a hydroxyl group where Melanotan II has an amide. This modification was designed to concentrate activity at central melanocortin receptors (MC3R and MC4R) while reducing the MC1R-mediated tanning effects of its parent compound.
In August 2004, Palatin signed a co-development agreement with King Pharmaceuticals, which paid $20 million upfront. Palatin initially pursued intranasal delivery, conducting Phase II trials for both female sexual dysfunction and male erectile dysfunction. However, the FDA placed a clinical hold on the intranasal trials in 2007 due to blood pressure concerns. Palatin pivoted to subcutaneous injection, which demonstrated fewer cardiovascular side effects, and ultimately completed the Phase III RECONNECT trials that led to FDA approval.
On June 21, 2019, the FDA approved bremelanotide injection under the brand name Vyleesi for the treatment of acquired, generalized HSDD in premenopausal women, making it the first melanocortin receptor agonist approved for sexual dysfunction and only the second FDA-approved treatment for HSDD.How It Differs from PDE5 Inhibitors
PT-141 operates through an entirely different mechanism than phosphodiesterase type 5 (PDE5) inhibitors such as sildenafil (Viagra), tadalafil (Cialis), and vardenafil (Levitra). PDE5 inhibitors work peripherally by blocking the enzyme that breaks down cyclic guanosine monophosphate (cGMP) in penile vascular smooth muscle, increasing blood flow in response to sexual stimulation. They address the mechanical component of erection but do not influence desire.
PT-141 works centrally through melanocortin receptor activation in the hypothalamus and limbic system, modulating the neurochemical pathways that generate sexual desire, arousal, and motivation. This fundamental distinction means PT-141 can address desire-based dysfunction where PDE5 inhibitors cannot, and its mechanism is not dependent on nitric oxide signaling pathways.How It Works
Melanocortin Receptor Activation
PT-141 binds to multiple melanocortin receptors, with its therapeutic effects primarily mediated through MC4R and MC3R. Compared to its parent compound Melanotan II, bremelanotide has reduced MC1R activity, which is why it produces minimal tanning effects. MC4R and MC3R, which are densely expressed in hypothalamic nuclei, particularly the paraventricular nucleus (PVN). Upon binding, PT-141 activates adenylyl cyclase and initiates cyclic adenosine monophosphate (cAMP) signaling cascades that modulate downstream neurotransmitter release.
The cyclic lactam structure of PT-141 creates a constrained conformation that fits melanocortin receptor binding pockets with high affinity, and this structural constraint also provides resistance to enzymatic degradation, giving it an elimination half-life of approximately 2.7 hours and biological effects that persist well beyond its plasma half-life.Central Nervous System Sexual Response Pathway
MC4R activation in the paraventricular nucleus of the hypothalamus is the primary driver of PT-141's sexual function effects. Studies using MC4R knockout animal models demonstrate abolished erectogenic responses to melanocortin agonists, confirming the receptor's essential role. Activation of MC4R modulates central dopaminergic pathways involved in sexual desire, arousal, and orgasm. This produces both the motivational (desire) and physiological (genital blood flow) components of sexual response.
PT-141's activity at MC3R may contribute additional motivational and appetitive dimensions to sexual arousal, addressing the "wanting" component of desire rather than solely the physical response. The FDA prescribing information notes that the precise mechanism by which bremelanotide improves HSDD remains incompletely characterized, though the melanocortin receptor pathway is clearly implicated.
Distinction from PDE5 Inhibitors
PT-141's central mechanism carries significant clinical implications. PDE5 inhibitors require sexual stimulation to be effective and only enhance the vascular response once arousal has occurred. PT-141 acts upstream of arousal, working at the level of desire and motivation in the brain. This makes it pharmacologically suited for conditions like HSDD, where the fundamental deficit is in desire itself rather than in the genital vascular response.
Furthermore, PT-141's mechanism does not rely on nitric oxide signaling, which means it can theoretically provide benefit even when nitric oxide pathways are impaired, as occurs in some forms of erectile dysfunction that are refractory to PDE5 inhibitors.Effects on Both Sexes
While PT-141 is FDA-approved only for premenopausal women with HSDD, research has demonstrated effects in both sexes. In women, the RECONNECT Phase III trials showed statistically significant improvements in sexual desire scores and reductions in distress associated with low desire. In men, Phase IIB trials demonstrated positive erectile responses in 33.5% of bremelanotide-treated patients versus 8.5% on placebo. A separate study demonstrated that bremelanotide could salvage erectile function in men who had failed sildenafil therapy, with co-administration producing significantly enhanced responses compared to sildenafil alone.
Real-world clinical data from sexual medicine clinics report improvements across multiple domains in men, including desire (39% of responders), erectile function (52%), orgasm (17%), and reduced performance anxiety (39%).Dosage Protocols
FDA-Approved Dosing (Vyleesi):
- 1.75 mg subcutaneously, administered at least 45 minutes before anticipated sexual activity
- Maximum one dose per 24-hour period
- Maximum 8 doses per month
- Patients should determine their optimal timing based on personal experience with onset and duration of effects
Off-Label Dosing Considerations:
Off-label use in men typically follows the same 1.75 mg subcutaneous dose, though some clinicians adjust within a range of 1 to 2 mg based on individual response and tolerability. Lower starting doses (0.5 to 1 mg) may be considered for first-time users to assess tolerance, particularly regarding nausea. Anti-nausea medication such as ondansetron taken 30 minutes before PT-141 can reduce gastrointestinal side effects.
The monthly frequency limit of 8 doses is based on the prescribing information and reflects the on-demand nature of the drug. PT-141 is not intended for daily use, and dose frequency should be kept to the minimum effective amount.
How to Use / Administration Methods
PT-141 is administered via subcutaneous injection. The FDA-approved Vyleesi product is supplied as a single-dose, pre-filled auto-injector containing 1.75 mg/0.3 mL of bremelanotide, designed for patient self-administration.
Injection Sites:
- Abdomen (preferred)
- Anterior thigh
Administration Procedure:
- Select the injection site and clean with an alcohol swab
- Pinch a fold of skin at the injection site
- Insert the auto-injector or needle at a 45 to 90 degree angle
- Administer the injection and hold for several seconds before withdrawing
- Apply gentle pressure with gauze; do not rub
- Rotate injection sites between doses to prevent local reactions
Timing: Administer at least 45 minutes before anticipated sexual activity. Based on pharmacokinetic data showing peak plasma concentrations at 30 to 60 minutes and maximal therapeutic effects at 2 to 4 hours, many users find injecting 1 to 2 hours before activity provides optimal results.
Intranasal formulations were explored during development but were abandoned due to blood pressure concerns. Some compounding pharmacies offer nasal spray preparations off-label, though the subcutaneous route has superior and more predictable bioavailability (approximately 100% for subcutaneous injection).
Results Timelines
0 to 30 minutes post-injection:
- Peptide enters systemic circulation and begins receptor binding
- Mild injection site warmth or redness may occur
- Nausea, if it occurs, typically begins within this window
30 to 60 minutes:
- Peak plasma concentration reached
- Initial onset of effects reported by many users
- Flushing and warmth may become apparent
1 to 4 hours:
- Maximal therapeutic window
- Effects on desire, arousal, and genital sensitivity are most pronounced
- Blood pressure elevation peaks between 2 to 4 hours post-dose
4 to 8 hours:
- Therapeutic effects gradually diminish
- Despite a plasma half-life of approximately 2.7 hours (range 1.9 to 4.0 hours), biological effects on sexual function persist for 6 to 8 hours in clinical observations, likely reflecting receptor residence time and downstream neurochemical changes
8 to 12 hours:
- Blood pressure and heart rate return to baseline
- Systemic clearance is essentially complete within 8 to 10 hours
- 64.8% is excreted in urine and 22.8% in feces
Individual response varies. Some users report effects within 15 to 20 minutes, while others require up to 90 minutes for onset. The prescribing information advises patients to determine their own optimal timing through experience.
Research Evidence
RECONNECT Phase III Trials
The approval of Vyleesi was based on two identical Phase III, randomized, double-blind, placebo-controlled, multicenter trials (RECONNECT) evaluating bremelanotide 1.75 mg versus placebo in 1,267 randomized premenopausal women with acquired, generalized HSDD. Patients were randomized 1:1 to 24 weeks of on-demand treatment.
The coprimary efficacy endpoints were change from baseline to end-of-study in the Female Sexual Function Index desire domain score (FSFI-D) and the Female Sexual Distress Scale Desire/Arousal/Orgasm item 13 (FSDS-DAO-13).
Both studies met both coprimary endpoints. In the integrated analysis, bremelanotide produced statistically significant increases in sexual desire (P < 0.001) and statistically significant reductions in distress related to low sexual desire (P < 0.001) compared to placebo. Approximately 25% of patients treated with bremelanotide achieved an increase of 1.2 or more in their desire score, compared to approximately 17% of placebo-treated patients. Benefits were consistent across age, weight, and body mass index subgroups.
Long-Term Extension Data
An open-label extension study assessed long-term safety and efficacy beyond the initial 24-week trial period. Results demonstrated that improvements in desire and reductions in distress were maintained with continued on-demand use, and no new safety signals emerged with prolonged exposure.
Male Erectile Dysfunction Studies
A randomized, double-blind, placebo-controlled trial evaluated bremelanotide in men with erectile dysfunction, demonstrating positive clinical responses in 33.5% of bremelanotide-treated patients versus 8.5% on placebo. A separate salvage study in sildenafil non-responders showed that bremelanotide co-administered with sildenafil produced significantly enhanced erectile responses compared to sildenafil alone.
Palatin Technologies initiated a Phase II study of bremelanotide co-administered with a PDE5 inhibitor for erectile dysfunction in men who do not respond to PDE5 inhibitor monotherapy. Results from this ongoing program will inform whether bremelanotide receives a future male indication.
Early Phase Research
Phase I and II studies by Molinoff et al. and Diamond et al. established the proof of concept for melanocortin agonists in sexual dysfunction, demonstrating dose-dependent effects on subjective arousal and physiological measures in both men and women. These early studies confirmed the central mechanism of action and informed the dose selection for the pivotal Phase III program.
Stacking
PT-141 is generally used as a standalone agent for sexual dysfunction. Its mechanism of action is distinct from other therapeutic classes, and combination use requires careful consideration.
PT-141 with PDE5 Inhibitors: Research has explored co-administration with sildenafil for men with refractory erectile dysfunction, with results suggesting synergistic benefit. However, caution is warranted regarding concurrent use of PT-141 with PDE5 inhibitors due to the combined risk of hypertension and, in men, priapism. Any such combination should only be undertaken under direct medical supervision.
PT-141 and Melanotan II: These two peptides should not be used simultaneously due to overlapping melanocortin receptor activity, which could amplify both therapeutic and adverse effects unpredictably. Some users alternate between Melanotan II for tanning and PT-141 for sexual function, using them on separate occasions. See PT-141 vs Melanotan II for a full comparison.
Other Peptide Combinations: PT-141 is sometimes used alongside peptides with unrelated mechanisms, such as BPC-157 for tissue healing or growth hormone secretagogues for body composition goals. No pharmacological interactions between PT-141 and these peptide classes have been established in research, but multi-peptide regimens increase the complexity of side effect management.
Reconstitution, Storage & Prep
Vyleesi (FDA-Approved Product):
Vyleesi is supplied as a pre-filled, single-dose auto-injector requiring no reconstitution. Store at 20 to 25 degrees Celsius (68 to 77 degrees Fahrenheit), with excursions permitted to 15 to 30 degrees Celsius.
Research-Grade Lyophilized Powder:
PT-141 is available as lyophilized powder, typically in 10 mg vials, requiring reconstitution before use.
Reconstitution Process:
- Allow the vial to reach room temperature
- Using a sterile syringe, draw the appropriate volume of bacteriostatic water (preferred for multi-use vials) or sterile water
- Inject the water slowly down the inside wall of the vial; do not spray directly onto the powder
- Gently swirl until fully dissolved; do not shake
- The solution should be clear and colorless; discard if cloudy or particulate matter is visible
Common Reconstitution Ratio:
- 2 mL bacteriostatic water per 10 mg vial yields 5 mg/mL (1.75 mg = 0.35 mL / 35 units on an insulin syringe)
Storage Guidelines:
- Unreconstituted powder: Store desiccated below -18 degrees Celsius for long-term storage; stable at room temperature for up to 3 weeks
- Reconstituted solution: Refrigerate at 2 to 8 degrees Celsius and use within 30 days
- Protect from light and avoid repeated freeze-thaw cycles
- Use insulin syringes (29 to 31 gauge) for subcutaneous administration
Side Effects
Very Common (greater than 10%):
- Nausea (40% of patients in clinical trials vs 1% placebo), typically occurring within 30 minutes of injection and lasting approximately 2 hours; most pronounced with the first dose and diminishing with subsequent use
- Flushing (20%)
- Injection site reactions (13%)
- Headache (11%)
Common (1 to 10%):
- Vomiting (4.8%)
- Cough (3.3%)
- Fatigue (3.2%)
- Hot flashes (2.7%)
- Paresthesia (2.6%)
- Dizziness (2.2%)
- Nasal congestion (2.1%)
- Upper respiratory tract infection
- Transient skin hyperpigmentation at injection site
Cardiovascular Effects:
PT-141 causes transient increases in blood pressure, with peak elevations of approximately 6 mmHg systolic and 3 mmHg diastolic occurring 2 to 4 hours post-dose, accompanied by a reduction in heart rate of up to 5 beats per minute. Blood pressure and heart rate return to baseline within 12 hours. To minimize cardiovascular risk, patients should not exceed one dose per 24-hour period. This blood pressure elevation was the basis for the FDA's 2007 clinical hold on the intranasal formulation, and the cardiovascular warning remains on the approved Vyleesi label.
Contraindications:
- Uncontrolled hypertension or known cardiovascular disease
- Patients at high risk for cardiovascular events
Special Precautions:
The FDA prescribing information does not carry a boxed warning, but includes warnings and precautions regarding cardiovascular effects. Blood pressure should be well-controlled before initiating therapy, and periodic monitoring during treatment is recommended. PT-141 may reduce the rate and extent of absorption of concomitantly administered oral medications by slowing gastric motility, though clinical studies found this effect was not clinically relevant except for naltrexone, with which co-use should be avoided.
Anti-nausea medication such as ondansetron taken 30 minutes before PT-141 administration can significantly reduce the incidence and severity of nausea. Administering after a light meal may also help, though this has not been formally studied.
Legal Status / FDA
PT-141 (bremelanotide) is FDA-approved as Vyleesi for a single indication: acquired, generalized hypoactive sexual desire disorder in premenopausal women. It is available by prescription and covered by some insurance plans, though coverage varies. For a broader look at the legal status of peptides across jurisdictions, see the peptide legality guide.
Prescription Use: Any use of bremelanotide requires a prescription. Off-label prescribing for men or for indications other than HSDD in premenopausal women is legal at a physician's discretion but is not supported by FDA-approved labeling.
Compounding Pharmacies: PT-141 is available through compounding pharmacies, which may prepare it as injectable solutions or nasal spray formulations. Compounded preparations are not subject to the same manufacturing standards as FDA-approved products, and quality, purity, and potency can vary.
Research Chemical Market: PT-141 is widely available as a lyophilized research peptide sold "for research purposes only." These products are not subject to FDA oversight, and claims of purity should be independently verified. Products purchased through unregulated channels carry risks related to contamination, mislabeling, and inconsistent potency.
International Status: Regulatory status varies by jurisdiction. In most countries, bremelanotide is not approved for any indication outside the United States, and importation may be subject to customs restrictions.
Sports / WADA
Bremelanotide is not listed by name on the 2025 WADA Prohibited List. However, as a synthetic peptide hormone analog and melanocortin receptor agonist, it may be captured under the broader language of category S2 (Peptide Hormones, Growth Factors, Related Substances, and Mimetics), which prohibits such substances and their mimetics both in-competition and out-of-competition.
Athletes subject to anti-doping regulations should not use PT-141 under any circumstances, regardless of the route of administration or clinical justification. Its parent compound, Melanotan II, is also explicitly prohibited. A Therapeutic Use Exemption (TUE) for PT-141 would be difficult to obtain given that HSDD is not a condition recognized as requiring treatment with a banned substance for an athlete to compete.
Athletes should also be aware that research-grade peptide products may contain undeclared substances that could independently trigger a positive anti-doping test.
Conclusion
PT-141 (bremelanotide) represents a genuinely novel pharmacological approach to sexual dysfunction, working through the melanocortin receptor system in the brain to address desire at its neurological source. Its FDA approval as Vyleesi in 2019 validated decades of melanocortin research and provided the first centrally-acting, non-hormonal, on-demand treatment for HSDD in premenopausal women.
The RECONNECT Phase III trials demonstrated statistically significant improvements in both sexual desire and associated distress, though the absolute treatment effect was modest, with approximately 25% of treated patients achieving clinically meaningful improvement versus 17% on placebo. The side effect profile is dominated by nausea, which affects 40% of patients but diminishes with continued use, along with transient cardiovascular effects that require attention in patients with hypertension or cardiovascular risk.
Research in male sexual dysfunction, including combination therapy with PDE5 inhibitors for refractory erectile dysfunction, suggests PT-141 may eventually gain broader indications. For now, off-label use in men continues to grow in clinical practice despite the absence of formal FDA approval for male indications. As with any peptide therapy, the quality and safety of the product depend heavily on the source, and FDA-approved Vyleesi remains the only formulation with guaranteed manufacturing standards.